Lipodystrophy - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lipodystrophy - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Lipodystrophy - Pipeline Review, H1 2016', provides an overview of the Lipodystrophy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Lipodystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lipodystrophy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lipodystrophy
- The report reviews pipeline therapeutics for Lipodystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Lipodystrophy therapeutics and enlists all their major and minor projects
- The report assesses Lipodystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Lipodystrophy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Lipodystrophy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lipodystrophy Overview 6
Therapeutics Development 7
Pipeline Products for Lipodystrophy - Overview 7
Lipodystrophy - Therapeutics under Development by Companies 8
Lipodystrophy - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Lipodystrophy - Products under Development by Companies 12
Lipodystrophy - Companies Involved in Therapeutics Development 13
Aegerion Pharmaceuticals, Inc. 13
Ambrx, Inc. 14
Bolder Biotechnology, Inc. 15
Galmed Pharmaceuticals Ltd. 16
Theratechnologies Inc. 17
Zydus Cadila Healthcare Limited 18
Lipodystrophy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Aramchol - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ARX-328 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
BBT-031 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
metreleptin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
saroglitazar - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
tesamorelin acetate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
volanesorsen sodium - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Lipodystrophy - Recent Pipeline Updates 41
Lipodystrophy - Dormant Projects 55
Lipodystrophy - Product Development Milestones 56
Featured News & Press Releases 56
Mar 08, 2016: Theratechnologies : Mexico Approves the 1mg/vial Presentation of EGRIFTA(R) (tesamorelin for injection) 56
Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study 56
Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease 57
Aug 11, 2015: AOP Orphan Announces Launch of Access Program for the World's First Drug against Lipodystrophy in HIV Patients, EGRIFTA, in Europe 57
Jul 14, 2015: EGRIFTA (Tesamorelin for Injection) Approved in Mexico 58
Jun 09, 2014: Galmed Pharmaceuticals Announces the Filing of a Provisional Patent Application for the Use of Aramchol for the Treatment of Lipodystrophy 58
May 29, 2014: Zydus Explores Newer Treatment Options With its Breakthrough Drug, Lipaglyn 59
May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States 59
May 20, 2014: Theratechnologies Inc.: Update on Availability of EGRIFTA in the United States 60
Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development for Lipodystrophy, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Lipodystrophy - Pipeline by Aegerion Pharmaceuticals, Inc., H1 2016 13
Lipodystrophy - Pipeline by Ambrx, Inc., H1 2016 14
Lipodystrophy - Pipeline by Bolder Biotechnology, Inc., H1 2016 15
Lipodystrophy - Pipeline by Galmed Pharmaceuticals Ltd., H1 2016 16
Lipodystrophy - Pipeline by Theratechnologies Inc., H1 2016 17
Lipodystrophy - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Lipodystrophy Therapeutics - Recent Pipeline Updates, H1 2016 41
Lipodystrophy - Dormant Projects, H1 2016 55